Biovie (BIVI) Change in Account Payables (2013 - 2026)
Biovie (BIVI) posted Change in Account Payables of -$1.3 million for Q1 2026, down 196.69% sequentially from $1.4 million in Q4 2025, and down 220.0% YoY from $1.1 million in Q1 2025.
Biovie (BIVI) Change in Account Payables (2013 - 2026) Analysis & Trends
Biovie has reported Change in Account Payables for 14 years, with the latest figure at -$1.3 million in Q1 2026.
- Quarterly Change in Account Payables fell 220.0% year-over-year to -$1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$864528.0 (up 55.3% YoY) and the FY2025 annual result came in at -$1.4 million, down 1353.1% from the prior year.
- Change in Account Payables declined to -$1.3 million in Q1 2026 per BIVI's latest filing, from $1.4 million in the prior quarter.
- Over five years, Change in Account Payables peaked at $1.6 million in Q1 2023 and troughed at -$2.1 million in Q4 2024.
- A 5-year average of -$1256.4 and a median of -$133940.0 in 2024 frame the typical range for Change in Account Payables.
- The widest YoY moves for Change in Account Payables: up 448.93% in 2023, down 462.71% in 2023.
- Over 5 years, Change in Account Payables stood at $623080.0 in 2022, then soared by 43.37% to $893336.0 in 2023, then sank by 331.77% to -$2.1 million in 2024, then jumped by 165.54% to $1.4 million in 2025, then tumbled by 196.69% to -$1.3 million in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered -$1.3 million, $1.4 million, and -$633956.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | 2.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.09 Mn |
| Jun 30, 2026 | 2.09 Mn |
| Mar 31, 2026 | -1.31 Mn |
| Mar 31, 2026 | -1.31 Mn |
| Dec 31, 2025 | 1.36 Mn |
| Dec 31, 2025 | 1.36 Mn |
| Sep 30, 2025 | -633,956.00 |
| Sep 30, 2025 | -633,956.00 |
| Jun 30, 2025 | -275,520.00 |
| Jun 30, 2025 | -275,520.00 |
| Mar 31, 2025 | 1.09 Mn |
| Mar 31, 2025 | 1.09 Mn |
| Dec 31, 2024 | -2.07 Mn |
| Dec 31, 2024 | -2.07 Mn |
| Sep 30, 2024 | -133,940.00 |
| Sep 30, 2024 | -133,940.00 |
| Jun 30, 2024 | -822,842.00 |
| Jun 30, 2024 | -822,842.00 |
| Mar 31, 2024 | 801,658.00 |
| Mar 31, 2024 | 801,658.00 |